BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23637297)

  • 1. Clinical validation of the Abbott RealTime High Risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening.
    Hesselink AT; Meijer CJ; Poljak M; Berkhof J; van Kemenade FJ; van der Salm ML; Bogaarts M; Snijders PJ; Heideman DA
    J Clin Microbiol; 2013 Jul; 51(7):2409-10. PubMed ID: 23637297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region.
    Hesselink AT; Berkhof J; van der Salm ML; van Splunter AP; Geelen TH; van Kemenade FJ; Bleeker MG; Heideman DA
    J Clin Microbiol; 2014 Mar; 52(3):890-6. PubMed ID: 24391196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical validation of the cobas 4800 HPV test for cervical screening purposes.
    Heideman DA; Hesselink AT; Berkhof J; van Kemenade F; Melchers WJ; Daalmeijer NF; Verkuijten M; Meijer CJ; Snijders PJ
    J Clin Microbiol; 2011 Nov; 49(11):3983-5. PubMed ID: 21880968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a multiplex real time PCR assay for the detection of human papillomavirus infections on self-collected cervicovaginal lavage samples.
    Jentschke M; Soergel P; Hillemanns P
    J Virol Methods; 2013 Oct; 193(1):131-4. PubMed ID: 23707925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the detection of HPV-16, 18, 31, 33, and 45 by type-specific DNA- and E6/E7 mRNA-based assays of HPV DNA positive women with abnormal Pap smears.
    Salimović-Bešić I; Tomić-Čiča A; Smailji A; Hukić M
    J Virol Methods; 2013 Dec; 194(1-2):222-8. PubMed ID: 24036071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Abbott RealTime High-Risk Human Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA.
    Park Y; Lee E; Choi J; Jeong S; Kim HS
    J Clin Microbiol; 2012 Jul; 50(7):2359-65. PubMed ID: 22518863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening.
    Poljak M; Ostrbenk A; Seme K; Ucakar V; Hillemanns P; Bokal EV; Jancar N; Klavs I
    J Clin Microbiol; 2011 May; 49(5):1721-9. PubMed ID: 21430098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of careHPV and hybrid capture 2 assays for detection of high-risk human Papillomavirus DNA in cervical samples from HIV-1-infected African women.
    Ngou J; Magooa MP; Gilham C; Djigma F; Didelot MN; Kelly H; Yonli A; Sawadogo B; Lewis DA; Delany-Moretlwe S; Mayaud P; Segondy M;
    J Clin Microbiol; 2013 Dec; 51(12):4240-2. PubMed ID: 24108613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a new DNA test for detection of carcinogenic human papillomavirus.
    Castle PE; Gutierrez EC; Leitch SV; Maus CE; McMillian RA; Nussbaumer WA; Vaughan LM; Wheeler CM; Gravitt PE; Schiffman M
    J Clin Microbiol; 2011 Aug; 49(8):3029-32. PubMed ID: 21632892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical validation of a type-specific real-time quantitative human papillomavirus PCR against the performance of hybrid capture 2 for the purpose of cervical cancer screening.
    Depuydt CE; Benoy IH; Beert JF; Criel AM; Bogers JJ; Arbyn M
    J Clin Microbiol; 2012 Dec; 50(12):4073-7. PubMed ID: 23052314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Principles and analytical performance of Abbott RealTime High Risk HPV test.
    Huang S; Tang N; Mak WB; Erickson B; Salituro J; Li Y; Krumpe E; Schneider G; Yu H; Robinson J; Abravaya K
    J Clin Virol; 2009 Jul; 45 Suppl 1():S13-7. PubMed ID: 19651363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting.
    Carozzi FM; Burroni E; Bisanzi S; Puliti D; Confortini M; Giorgi Rossi P; Sani C; Scalisi A; Chini F
    J Clin Microbiol; 2011 Apr; 49(4):1446-51. PubMed ID: 21325553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Abbott RealTime High Risk HPV test and the Roche cobas 4800 HPV test using urine samples.
    Lim MC; Lee DH; Hwang SH; Hwang NR; Lee B; Shin HY; Jun JK; Yoo CW; Lee DO; Seo SS; Park SY; Joo J
    J Virol Methods; 2017 May; 243():74-79. PubMed ID: 28161277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus detection using the Abbott RealTime high-risk HPV tests compared with conventional nested PCR coupled to high-throughput sequencing of amplification products in cervical smear specimens from a Gabonese female population.
    Moussavou-Boundzanga P; Koumakpayi IH; Labouba I; Leroy EM; Belembaogo E; Berthet N
    Virol J; 2017 Dec; 14(1):241. PubMed ID: 29268766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies.
    Poljak M; Oštrbenk A
    Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):43-7. PubMed ID: 23836358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction of human papillomavirus DNA screening in the world: 15 years of experience.
    Castle PE; de Sanjosé S; Qiao YL; Belinson JL; Lazcano-Ponce E; Kinney W
    Vaccine; 2012 Nov; 30 Suppl 5():F117-22. PubMed ID: 23199954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Anyplex II HPV28 assay with the Hybrid Capture 2 assay for the detection of HPV infection.
    Kwon MJ; Roh KH; Park H; Woo HY
    J Clin Virol; 2014 Apr; 59(4):246-9. PubMed ID: 24568964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluation of AMPLICOR HPV PCR and Linear Array assays on SurePath liquid-based Pap samples for the detection of high-risk HPV genotypes.
    Chernesky M; Jang D; Portillo E; Smieja M; Chong S; Buracond S; Klingel M; El Sebai R; Kapala J; Patel J; Biers K; Harroun N; Doucette C; Sumner J
    J Clin Virol; 2011 Mar; 50(3):201-4. PubMed ID: 21195020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High performance of a new PCR-based urine assay for HPV-DNA detection and genotyping.
    Tanzi E; Bianchi S; Fasolo MM; Frati ER; Mazza F; Martinelli M; Colzani D; Beretta R; Zappa A; Orlando G
    J Med Virol; 2013 Jan; 85(1):91-8. PubMed ID: 23097252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-risk HPV detection and genotyping by APTIMA HPV using cervical samples.
    Pyne MT; Hamula CL; Tardif K; Law C; Schlaberg R
    J Virol Methods; 2015 Sep; 221():95-9. PubMed ID: 25956671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.